A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600 -Mutant High-Grade Glioma (HGG) (IND# 145355)

Medicine and Dentistry

1. Ganglioglioma 100%
2. Dabrafenib 100%
3. Trametinib 100%
4. Mitogen-Activated Protein Kinase 60%
5. Pediatrics 40%
6. Neoplasm 20%
7. MEK Inhibitor 20%
8. Combination Therapy 20%
9. Maintenance Therapy 20%
10. Disease Exacerbation 20%
11. Overall Survival 20%
12. Cancer 20%
13. Intracranial Tumor 20%
14. Tumor 20%
15. Event Free Survival 20%